697P - A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma
| Autor: | Cheng, A.-L., Yen, C.-J., Okusaka, T., Ikeda, M., Hsu, C.-H., Wu, S.-Y., Morizane, C., Hashimoto, Y., Ueshima, K., Ohtomo, T., Tanaka, T., Kudo, M. |
|---|---|
| Zdroj: | In Annals of Oncology October 2018 29 Supplement 8 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|